• OPEN AN ACCOUNT
Indian Indices
Sensex
77,540.83 3.11
( 0.00%)
Global Indices
Nasdaq
53,294.39 514.18
(0.97%)
Dow Jones
7,693.51 31.35
(0.41%)
Hang Seng
65,893.13 -323.66
(-0.49%)
Nikkei 225
10,809.01 60.85
(0.57%)
Forex
USD-INR
95.67 0.05
(0.05%)
EUR-INR
111.76 0.57
(0.51%)
GBP-INR
130.35 0.55
(0.42%)
JPY-INR
0.60 0.00
(0.11%)

EQUITY - MARKET SCREENER

Tata Consultancy Services Ltd
Industry :  Computers - Software - Large
BSE Code
ISIN Demat
Book Value()
532540
INE467B01029
234.0734112
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
TCS
15.44
831436.51
EPS(TTM)
Face Value()
Div & Yield %
148.84
1
4.79
 

cipla ltd
USFDA inspects Cipla subsidiary's manufacturing unit in New York
Jul 18,2026

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.